[an error occurred while processing this directive] | [an error occurred while processing this directive]
Imaging diagnosis of the medial group of retropharyngeal lymph nodes and the exploration of the optimization of target volume for protecting the swallowing structure in nasopharyngeal carcinoma
Zong Dan, Zhang Lanfang, Chen Cheng, Gu Dayong, He Xia, Huang Shengfu
Department of Radiation Oncology,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Affiliated Cancer Hospital of Nanjing Medical University,Nanjing 210009,China
AbstractObjective To clarify the diagnostic value of diffusion-weighed imaging (DWI) in the medial group of retropharyngeal lymph nodes in nasopharyngeal carcinoma,understand the clinical characteristics of retropharyngeal lymph nodes and explore the feasibility of optimizing the target volume of CTV60. Methods Clinical data of 437 patients with clinical stage Ⅰ-IVa nasopharyngeal carcinoma admitted to Jiangsu Cancer Hospital from 2011 to 2017 were retrospectively analyzed. All patients underwent magnetic resonance imaging (MRI),DWI (1000 s/mm2) and enhanced CT scans to analyze the clinical characteristics of retropharyngeal lymph nodes and investigate the dosimetric advantage and safety of CTV60 lower margin on the upper margin of C2. Results The medial lymph nodes with a transverse diameter of 2.0-19.0 mm were detected 13 of 437 patients,and 53.8% of the lymph nodes were measured 2-5 mm in transverse diameter. The medial lymph nodes were distributed between the superior margin of C1 and 1/3 of C3.Its occurrence was related to N stage,double cervical lymph node metastases,especially the transverse diameter of cervical lymph node> 3 cm. The sensitivity of DWI,T2 and enhanced CT were 100%,61.5% and 23.1%.After the special cases were excluded,the lower margin of CTV60 on the superior margin of C2 was separated. The radiation dose and volume of the swallowing structures were significantly decreased. The 5-year survival rate was 80% without recurrence in the optimized region. Conclusions The incidence of the medial group of retropharyngeal lymph nodes is low with a diameter of less than 5 mm. DWI possesses advantages in displaying the medial group of retropharyngeal lymph nodes. Isolating the lower margin of CTV60 from the superior margin of C2 is safe and feasible and has dosimetric advantages for protecting swallowing structure.
Zong Dan,Zhang Lanfang,Chen Cheng et al. Imaging diagnosis of the medial group of retropharyngeal lymph nodes and the exploration of the optimization of target volume for protecting the swallowing structure in nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1035-1040.
Zong Dan,Zhang Lanfang,Chen Cheng et al. Imaging diagnosis of the medial group of retropharyngeal lymph nodes and the exploration of the optimization of target volume for protecting the swallowing structure in nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1035-1040.
[1] Leong YH,Soon YY,Lee KM,et al. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy:a meta-analysis[J].Head Neck,2017,40(3):356-359.DOI:10.1002/hed.24993. [2] Nguyen NP,Moltz CC,Frank C,et al. Dysphagia following chemoradiation for locally advanced head and neck cancer[J].Ann Oncol,2004,15(3):383-388. [3] Li K,Yang L,Xin P,et al. Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy[J].Oral Oncol,2017,72(1):32-37.DOI:10.1016/j.oraloncology.2017.06.026. [4] Wu LR,Liu YT,Jiang N,et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy:an analysis of 614 patients from a single center[J].Oral Oncol,2017,69(1):26-32.DOI:10.1016/j.oraloncology.2017.03.015. [5] Messing BP,Ward EC,Lazarus CL,et al. Prophylactic swallow therapy for patients with head and neck cancer undergoing chemoradiotherapy:a randomized trial[J].Dysphagia,2017,32(4):487-500.DOI:10.1007/s00455-017-9790-6. [6] Ku PK,Yuen EH,Cheung DM,et al. Early swallowing problems in a cohort of patients with nasopharyngeal carcinoma:Symptomatology and videofluoroscopic findings[J].Laryngoscope,2007,117(1):142-146.DOI:10.1097/01.mlg.0000248738.55387.44. [7] Wang X,Hu C,Ying H,et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels[J].Radiother Oncol,2015,115(1):41-45.DOI:10.1016/j.radonc.2015.02.017. [8] Krisciunas GP,Sokoloff W,Stepas K,et al. Survey of usual practice:dysphagia therapy in head and neck cancer patients[J].Dysphagia,2012,27(4):538-549.DOI:10.1007/s00455-012-9404-2. [9] Wang JJ,Jiang RS,Yen TT,et al. Risk factors for recurrent pneumonia in post-irradiated patients with nasopharyngeal carcinoma[J].J Chin Med Assoc,2017,80(9):558-562.DOI:10.1016/j.jcma.2017.01.006. [10] Wu CH,Hsiao TY,Ko JY,et al. Dysphagia after radiotherapy:endoscopic examination of swallowing in patients with nasopharyngeal carcinoma[J].Ann Otol Rhinol Laryngol,2000,109(3):320-325.DOI:10.1177/000348940010900315. [11] Lovell SJ,Wong HB,Loh KS,et al. Impact of dysphagia on quality-of-life in nasopharyngeal carcinoma[J].Head Neck,2005,27(10):864-872.DOI:10.1002/hed.20250. [12] Oozeer NB,Corsar K,Glore RJ,et al. The impact of enteral feeding route on patient-reported long term swallowing outcome after chemoradiation for head and neck cancer[J].Oral Oncol,2011,47(10):980-983.DOI:10.1016/j.oraloncology.2011.07.011. [13] Batth SS,Caudell JJ,Chen AM.Practical considerations in reducing swallowing dysfunction following concurrent chemoradiotherapy with intensity-modulated radiotherapy for head and neck cancer[J].Head Neck,2014,36(2):291-298.DOI:10.1002/hed.23246. [14] Petkar I,Rooney K,Roe JW,et al. DARS:a phase Ⅲ randomised multicentre study of dysphagia-optimised intensity-modulated radiotherapy (Do-IMRT) versus standard intensity-modulated radiotherapy (S-IMRT) in head and neck cancer[J].BMC Cancer,2016,16(1):770.DOI:10.1186/s12885-016-2813-0. [15] Lam WW,Chan YL,Leung SF,et al. Retropharyngeal lymphadenopathy in nasopharyngeal carcinoma[J].Head Neck,1997,19(3):176-181.
2018, Vol. 27 
